|
Depression
|
Duloxetine hydrochloride
|
Major Depressive Disorder (MDD)
|
Neuropathic pain, generalized anxiety disorder (GAD), osteoarthritis, and stress incontinence
|
Approved
|
|
Fluoxetine hydrochloride
|
Major Depressive Disorder (MDD)
|
Premenstrual dysphoric disorder (PMDD)
|
Approved
|
|
Sibutramine hydrochloride
|
Major Depressive Disorder (MDD)
|
Obesity
|
Approved
|
|
Neurology
|
Atomoxetine hydrochloride
|
Parkinson’s disease (PD)
|
Attention-deficit hyperactivity disorder (ADHD)
|
Approved
|
|
Ropinirole hydrochloride
|
Hypertension (HTN)
|
Parkinson’s disease (PD)
|
Approved
|
|
Non-neurology
|
Minoxidil
|
Hypertension (HTN)
|
Hair loss
|
Approved
|
|
Finasteride
|
Benign prostatic hyperplasia (BPH)
|
Hair loss
|
Approved
|
|
Zidovudine
|
Failed clinical trials for cancer
|
Human immunodeficiency virus (HIV)
|
Approved
|
|
Sildenafil
|
Angina
|
Erectile dysfunction (ED) and pulmonary arterial hypertension (PAH)
|
Approved
|
|
Cancer
|
Auranofin
|
Rheumatoid arthritis (RA)
|
Gastrointestinal stromal tumor (GIST)
|
Approved
|
|
Imatinib
|
Chronic myeloid leukemia (CML)
|
Gastrointestinal stromal tumors (GIST)
|
Approved
|
|
Irinotecan hydrochloride
|
Colorectal cancer
|
Pancreatic cancer
|
Approved
|
|
Nelfinavir
|
Human immunodeficiency virus 1 (HIV-1)
|
Colorectal cancer, lung cancer, cervical cancer, pancreatic cancer, ovarian cancer, metastatic cancer
|
Investigational
|
| |
Metformin hydrochloride
|
Type 2 diabetes (T2DM)
|
Breast cancer, pancreatic cancer, endometrial cancer, colorectal cancer, and esophageal cancer
|
Investigational
|
|
Trastuzumab
|
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer
|
Metastatic breast cancer, gastric cancer, and early breast cancer
|
Approved
|
|
Sunitinib
|
Renal cell carcinoma (RCC) and Gastrointestinal stromal tumor (GIST)
|
Pancreatic neuroendocrine tumors (PNETs)
|
Approved
|
|
Crizotinib
|
Clinical trials for anaplastic large cell lymphoma (ALCL)
|
Non-small cell lung cancer (NSCLC)
|
Approved
|
|
Infectious
|
Thalidomide
|
Morning sickness (withdrawn)
|
Erythema nodosum leprosum (Leprosy)
|
Approved
|
|
Everolimus
|
Immunosuppressant
|
Pancreatic neuroendocrine tumors (PNETs), renal cell carcinoma (RCC), and subependymal giant cell astrocytoma (SEGA)
|
Approved
|
|
Sirolimus
|
Organ rejection in patients receiving renal transplants
|
Malaria
|
Investigational
|
|
Rare and orphan
|
Alefacept
|
Chronic plaque psoriasis
|
Rejection in patients receiving allogeneic solid organ transplants
|
Investigational
|
|
Indium In-111 pentetreotide
|
Agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors
|
Neuroendocrine tumors (NETs)
|
Investigational
|
